Donations from Didier Coeurnelle enable next phase of Robust Mouse Rejuvenation research program

Thanks to Didier’s generosity, in addition to an initial gift of €200,000 (approximately $220,000), up to a further €200,000 donated to LEVF before November 15th 2024 will be doubled.

Join forces with Didier & LEVF, and help us to launch the second phase of RMR!

Longevity Escape Velocity Foundation

— conducting and inspiring research to comprehensively cure and prevent human age-related disease.

“We are humanitarians first and foremost.”

— Dr. Aubrey de Grey

Projects

Robust Mouse Rejuvenation

Our flagship mouse longevity study will identify synergies between known rejuvenation therapies

Transplants On-Demand

We’re funding Keinice Bio’s novel cryopreservation technology to scale tissue and organ banking

Outreach & Events

Leadership

President & Chief Science Officer

Visionary biomedical gerontologist

Dr. Aubrey de Grey

David Wood

Executive Director

Veteran technology executive & futurist

News & Updates

In collaboration with primary author Professor Brian Kennedy, with input and enthusiastic endorsement from iconic researchers and leaders across the field of longevity medicine and allied fields, we are delighted to publish the Dublin Longevity Declaration: Consensus Recommendation to Immediately Expand Research on Extending Healthy Human Lifespans.

Combining rejuvenation interventions in rodents: a milestone in biomedical gerontology whose time has come

Our first peer-reviewed paper is now available to read free of charge.

Ever wondered what kind of planning goes into a study like LEVF's Robust Mouse Rejuvenation program? Our preparatory work included conducting a thorough survey of the data generated during past efforts to extend the healthy lifespan of rodents.

We're now making that information available to the community through the Rodent Aging Interventions Database (RAID) - a visual tool comparing the success achieved in published studies.

Robust Mouse Rejuvenation

Featured
October 6th, 2024

The milestone we have hit this time is that all 20 groups (10 male and 10 female) have now reached their last "cull point", i.e. the point where only eight mice of the original 50 are alive and we sacrifice two of them to store various tissues, as well as doing a lot of the non-invasive measurements on the others...

Read More →
August 17th, 2024

We're getting fairly near to the end of the study - but how near, we certainly can't yet say. Six of the 20 treatment groups, two male and four female, are now extinct, but the all-treatment groups of both sexes are still at 25% survival at over 35 months of age, which gives hope that the longest-lived mouse in the entire study will turn out to be fairly impressive...

Read More →
June 29th, 2024

This update marks a milestone, namely that one treatment group of each sex has now entirely expired. For males it's the group getting only telomerase, and for females it's the group getting everything except rapamycin…

Read More →
May 7th, 2024

The survival curves continue to provide tantalising but preliminary information. Particularly exciting is how long the all-control group took, measured from the start of the study, to reach the survival percentage that the all-treatment group is currently at…

Read More →

Articles

The Case for: Senolytics
Jan 10, 2024

The first in a new series of articles by LEV Foundation’s Chief Science Monitor, Maximus Peto, introducing the interventions used in the first Robust Mouse Rejuvenation study and exploring the scientific rationale for their selection.